Epithelial ovarian cancer has a major heritable component, but the known susceptibility genes explain less than half the excess familial risk1. We performed a genome-wide association study (GWAS) to identify common ovarian cancer susceptibility alleles. We evaluated 507,094 SNPs genotyped in 1,817 cases and 2,353 controls from the UK and ∼2 million imputed SNPs. We genotyped the 22,790 top ranked SNPs in 4,274 cases and 4,809 controls of European ancestry from Europe, USA and Australia. We identified 12 SNPs at 9p22 associated with disease risk (P < 10−8). The most significant SNP (rs3814113; P = 2.5 × 10−17) was genotyped in a further 2,670 ovarian cancer cases and 4,668 controls, confirming its association (combined data odds ratio (OR) = 0.82, 95% confidence interval (CI) 0.79–0.86, Ptrend = 5.1 × 10−19). The association differs by histological subtype, being strongest for serous ovarian cancers (OR 0.77, 95% CI 0.73–0.81, Ptrend = 4.1 × 10−21).
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Pharoah, P.D. & Ponder, B.A. The genetics of ovarian cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 16, 449–468 (2002).
Stratton, J.F., Pharoah, P., Smith, S.K., Easton, D. & Ponder, B.A. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br. J. Obstet. Gynaecol. 105, 493–499 (1998).
Antoniou, A.C. & Easton, D.F. Risk prediction models for familial breast cancer. Future Oncol. 2, 257–274 (2006).
Gayther, S.A. et al. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. Am. J. Hum. Genet. 65, 1021–1029 (1999).
Pharoah, P.D., Antoniou, A.C., Easton, D.F. & Ponder, B.A. Polygenes, risk prediction, and targeted prevention of breast cancer. N. Engl. J. Med. 358, 2796–2803 (2008).
Easton, D.F. et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447, 1087–1093 (2007).
Thomas, G. et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat. Genet. 40, 310–315 (2008).
Brown, K.M. et al. Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat. Genet. 40, 838–840 (2008).
Eeles, R.A. et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat. Genet. 40, 316–321 (2008).
Gudbjartsson, D.F. et al. ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat. Genet. 40, 886–891 (2008).
Broderick, P. et al. A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nat. Genet. 39, 1315–1317 (2007).
Yeager, M. et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet. 39, 645–649 (2007).
de Bakker, P.I. et al. Practical aspects of imputation-driven meta-analysis of genome-wide association studies. Hum. Mol. Genet. 17, R122–R128 (2008).
Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661–678 (2007).
Vanhoutteghem, A. & Djian, P. Basonuclin 2: an extremely conserved homolog of the zinc finger protein basonuclin. Proc. Natl. Acad. Sci. USA 101, 3468–3473 (2004).
Vanhoutteghem, A. & Djian, P. The human basonuclin 2 gene has the potential to generate nearly 90,000 mRNA isoforms encoding over 2000 different proteins. Genomics 89, 44–58 (2007).
Stranger, B.E. et al. Population genomics of human gene expression. Nat. Genet. 39, 1217–1224 (2007).
Romano, R.A., Li, H., Tummala, R., Maul, R. & Sinha, S. Identification of Basonuclin2, a DNA-binding zinc-finger protein expressed in germ tissues and skin keratinocytes. Genomics 83, 821–833 (2004).
O'Driscoll, L. et al. Investigation of the molecular profile of basal cell carcinoma using whole genome microarrays. Mol. Cancer 5, 74 (2006).
Song, H. et al. Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. Hum. Mol. Genet. 18, 2297–2304 (2009).
Quaye, L. et al. The effects of common genetic variants in oncogenes on ovarian cancer survival. Clin. Cancer Res. 14, 5833–5839 (2008).
Pearce, C.L. et al. Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. Br. J. Cancer 100, 412–420 (2009).
Schildkraut, J.M. et al. Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res. 69, 2349–2357 (2009).
Ramus, S.J. et al. Consortium analysis of 7 candidate SNPs for ovarian cancer. Int. J. Cancer 123, 380–388 (2008).
Ghoussaini, M. et al. Multiple Loci with different cancer specificities within the 8q24 gene desert. J. Natl. Cancer Inst. 100, 962–966 (2008).
Song, H. et al. Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer. Cancer Res. 68, 8837–8842 (2008).
Gayther, S.A. et al. Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res. 67, 3027–3035 (2007).
Song, H. et al. Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer. PLoS ONE 2, e268 (2007).
Easton, D.F. & Eeles, R.A. Genome-wide association studies in cancer. Hum. Mol. Genet. 17, R109–R115 (2008).
Rubin, S.C. et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N. Engl. J. Med. 335, 1413–1416 (1996).
Lakhani, S.R. et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin. Cancer Res. 10, 2473–2481 (2004).
Domanska, K., Malander, S., Masback, A. & Nilbert, M. Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40. Int. J. Gynecol. Cancer 17, 789–793 (2007).
Tothill, R.W. et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14, 5198–5208 (2008).
Lord, C.J. & Ashworth, A. Targeted therapy for cancer using PARP inhibitors. Curr. Opin. Pharmacol. 8, 363–369 (2008).
Drew, Y. & Calvert, H. The potential of PARP inhibitors in genetic breast and ovarian cancers. Ann. NY Acad. Sci. 1138, 136–145 (2008).
Houlston, R.S. et al. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat. Genet. 40, 1426–1435 (2008).
Sankararaman, S., Sridhar, S., Kimmel, G. & Halperin, E. Estimating local ancestry in admixed populations. Am. J. Hum. Genet. 82, 290–303 (2008).
Scheet, P. & Stephens, M. A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase. Am. J. Hum. Genet. 78, 629–644 (2006).
Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat. Genet. 39, 906–913 (2007).
Udler, M.S. et al. FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Hum. Mol. Genet. 18, 1692–1703 (2009).
We thank all the individuals who took part in this study. We thank all the researchers, clinicians and administrative staff who have enabled the many studies contributing to this work. In particular we thank A. Ryan and J. Ford (UKOPS); J. Morrison, the SEARCH team, U. Eilber and T. Koehler (GER); D. Bowtell, A. deFazio, D. Gertig, A. Green (AOCS); A. Green, P. Parsons, N. Hayward, D. Whiteman (ACS); L. Brinton, M. Sherman, A. Hutchinson, N. Szeszenia-Dabrowska, B. Peplonska, W. Zatonski, A. Soni, P. Chao, M. Stagner (POL1); N. Bogdanova, S. Haubold, P. Schürmann, F. Kramer, T.-W. Park-Simon, K. Beer-Grondke and D. Schmidt (HJOCS). The genotyping and data analysis for this study was supported by a project grant from Cancer Research UK. We acknowledge the computational resources provided by the University of Cambridge (CamGrid). The Ovarian Cancer Association Consortium is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith. D.F.E. and P.D.P.P. are supported by Cancer Research UK, S.J.R. by the Mermaid/Eve Appeal, G.C.-T. and P.M.W. by the NHMRC, and P.A.F. by the Deutsche Krebshilfe e.V. Funding of the constituent studies was provided by the Roswell Park Alliance, the Danish Cancer Society and the US National Cancer Institute (CA71766, CA16056, R01 CA61107, R01 CA122443, R01 CA054419, P50 CA105009,R01CA114343, R01 CA87538, R01 CA112523, R01-CA- 58598, N01-CN-55424 and N01-PC-35137, R01-CA-122443, CA-58860, CA-92044), the US Army Medical Research and Material Command (DAMD17-01-1-0729), the Cancer Council Tasmania and Cancer Foundation of Western Australia (AOCS study), the National Health and Medical Research Council of Australia (199600; ACS study), German Federal Ministry of Education and Research of Germany Programme of Clinical Biomedical Research (01 GB 9401), and the genotyping in part by the state of Baden-Württemberg through Medical Faculty of the University of Ulm (P.685; GER), the Mayo Foundation and the Lon V. Smith Foundation (grant LVS-39420). The UKOPS study is funded by the Oak Foundation. Some of this work was undertaken at University College Hospital, London which receives a proportion of its funding from the UK Department of Health's National Institute for Health Research Biomedical Research Centre funding scheme.
About this article
Cite this article
Song, H., Ramus, S., Tyrer, J. et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 41, 996–1000 (2009). https://doi.org/10.1038/ng.424
Functional Interrogation of Enhancer Connectome Prioritizes Candidate Target Genes at Ovarian Cancer Susceptibility Loci
Frontiers in Genetics (2021)
Journal of Translational Medicine (2020)
Current Epidemiology Reports (2020)
Ovarian Cancer Risk Variants Are Enriched in Histotype-Specific Enhancers and Disrupt Transcription Factor Binding Sites
The American Journal of Human Genetics (2020)